GENKYOTEX;SERUM INSTITUTE OF INDIA PRIVATE LIMITED;REMI PALMANTIER;YOLANDE MISSERI;CAROLINE DIVEU-SADER;SUNIL GAIROLA;MANISH GAUTAM;HARISH RAO;UMESH SHALIGRAM
The invention relates to the use of a polypeptide derived from the adenylate cyclase of a Bordetella sp .(CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of Bordetella pertussis, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by Bordetella sp. or in a combination composition encompassing said acellular immunogenic composition.
